EUVIMEDEUVIMED entdecken
Crossref

A Lignan from Alnus japonica Activates Myogenesis and Alleviates Dexamethasone-induced Myotube Atrophy

Hyejin Lee, Ji Hye Jeong, Seung Hwan Hwang, Sung Hum Yeon, Jae-Ha Ryu

Planta Medica · 01.04.2023 · 89 (05) · 484-492

DOI: 10.1055/a-1891-3366 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.04.2023. Verfasst von Hyejin Lee und 4 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Pharmaceutical Sciences and College of Pharmacy, Sookmyung Women's University, Seoul, Korea. Hauptthemen laut MEDLINE: Alnus, Lignans. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Research Foundation of Korea, Korean Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To find inhibitors against skeletal muscle loss, we isolated a lignan compound ((−)-(2R,3R-1,4-O-diferuloylsecoisolarciresinol, DFS) from the stem of Alnus japonica. C2C12 myoblasts were treated with DFS during differentiation. To induce an in vitro atrophic condition, differentiated myotubes were treated with dexamethasone (a synthetic glucocorticoid). DFS (10 nM) increased expression levels of myogenic factors and the number of multi-nucleated myotubes expressing myosin heavy chain (MHC). The myogenic potential of DFS could be attributed to p38 MAPK activation. DFS also protected against dexamethasone-induced damage, showing increased expression of MHC and mammalian target of rapamycin (mTOR), a major anabolic factor. Under atrophic condition, the anti-myopathy effect of DFS was associated with inactivation of NF-κB signaling pathway and the subsequent suppression of muscle degradative E3 ligases and myostatin. DFS treatment also restored fast muscle fiber (type II a, II b, and II x), known to be susceptible to dexamethasone. These results indicate that DFS isolated from A. japonica can stimulate myogenesis via p38 MAPK activation and alleviate muscle atrophy by modulating the expression of genes associated with muscle protein anabolism/catabolism. Thus, we propose that DFS can be used as a pharmacological and nutraceutical agent for increasing muscle strength or protecting muscle loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlnusLignansMuscle, SkeletalMuscular AtrophyMuscle Fibers, SkeletalDexamethasoneMuscle Developmentp38 Mitogen-Activated Protein Kinases

Substanzen

LignansDexamethasonep38 Mitogen-Activated Protein Kinases

Autor:innen und Institutionen

  • Research Institute of Pharmaceutical Sciences and College of Pharmacy, Sookmyung Women's University, Seoul, Korea.
  • R & D Center, Huons Co., Ltd., Gyeonggi-Do, Korea.

Förderung

  • National Research Foundation of Korea
  • Korean Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET)

Zitieren

APA

Lee, H., Jeong, J. H., Hwang, S. H., Yeon, S. H., & Ryu, J. H. (2023). A Lignan from Alnus japonica Activates Myogenesis and Alleviates Dexamethasone-induced Myotube Atrophy. Planta Medica, 89(05), 484-492. https://doi.org/10.1055/a-1891-3366

Vancouver

Lee H, Jeong JH, Hwang SH, Yeon SH, Ryu JH. A Lignan from Alnus japonica Activates Myogenesis and Alleviates Dexamethasone-induced Myotube Atrophy. Planta Medica. 2023;89(05):484-492. doi:10.1055/a-1891-3366

BibTeX
@article{Lee2023,
  author = {Lee, Hyejin and Jeong, Ji Hye and Hwang, Seung Hwan and Yeon, Sung Hum and Ryu, Jae-Ha},
  title = {A Lignan from Alnus japonica Activates Myogenesis and Alleviates Dexamethasone-induced Myotube Atrophy},
  journal = {Planta Medica},
  year = {2023},
  volume = {89},
  number = {05},
  pages = {484--492},
  doi = {10.1055/a-1891-3366}
}
Kostenlos starten →